Tenet Healthcare (THC) to Release Earnings on Wednesday

Tenet Healthcare (NYSE:THC) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $4.05 per share and revenue of $5.4680 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 11, 2026 at 10:00 AM ET.

Tenet Healthcare Stock Performance

NYSE THC opened at $193.32 on Wednesday. The stock has a market cap of $16.99 billion, a PE ratio of 13.25, a P/E/G ratio of 0.80 and a beta of 1.44. Tenet Healthcare has a twelve month low of $109.82 and a twelve month high of $222.82. The stock has a fifty day simple moving average of $199.86 and a 200-day simple moving average of $192.38. The company has a current ratio of 1.71, a quick ratio of 1.64 and a debt-to-equity ratio of 2.27.

Insider Buying and Selling

In other news, Director Nadja West sold 2,178 shares of Tenet Healthcare stock in a transaction on Monday, December 15th. The shares were sold at an average price of $197.47, for a total transaction of $430,089.66. Following the completion of the sale, the director directly owned 28,480 shares of the company’s stock, valued at approximately $5,623,945.60. The trade was a 7.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider R. Scott Ramsey sold 13,322 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $205.11, for a total value of $2,732,475.42. The SEC filing for this sale provides additional information. 0.81% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tenet Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the business. Boston Partners boosted its holdings in Tenet Healthcare by 38.8% in the third quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after purchasing an additional 880,413 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Tenet Healthcare by 8.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock worth $373,020,000 after buying an additional 157,109 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Tenet Healthcare by 62.3% in the 3rd quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock valued at $380,989,000 after buying an additional 720,160 shares during the last quarter. Bank of America Corp DE raised its stake in Tenet Healthcare by 9.6% during the 3rd quarter. Bank of America Corp DE now owns 1,078,585 shares of the company’s stock worth $218,996,000 after acquiring an additional 94,903 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in Tenet Healthcare by 375.7% in the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock valued at $139,085,000 after acquiring an additional 624,125 shares during the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on THC. Truist Financial reiterated a “buy” rating and set a $240.00 price target (up from $225.00) on shares of Tenet Healthcare in a research report on Monday, November 3rd. TD Cowen reissued a “buy” rating on shares of Tenet Healthcare in a research report on Wednesday, January 7th. Morgan Stanley restated an “overweight” rating and set a $247.00 price target on shares of Tenet Healthcare in a research report on Thursday, December 18th. JPMorgan Chase & Co. boosted their price objective on Tenet Healthcare from $200.00 to $230.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Finally, Raymond James Financial set a $245.00 target price on Tenet Healthcare in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Tenet Healthcare has an average rating of “Moderate Buy” and a consensus price target of $233.88.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.